Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
ConditionNeurocognitive Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBaptist Health South Florida
About this trial
This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.
Eligibility criteria
Qualifiers
All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and/or antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)
Life expectancy ≥ 6 months
Willingness to participate in ongoing registration study
Disqualifiers
Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)
Pediatric patients (<18 years old), pregnant women, and prisoners.
Trial design
Treatments tested in this trial
- Observational study
Treatment groups
No treatment groups listed
Sponsors and collaborators
Baptist Health South Florida
Lead sponsor
Brainlab AG
Collaborator
Source ClinicalTrials.gov